Search

Displaying results 1051 - 1060 of 1723 in total
  1. Drug

    Niacin

    go.drugbank.com/drugs/DB00627
    ApprovedInvestigationalNutraceutical

    Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.

    Mixtures: O-Cal FA multivitamin, O-Cal FA multivitamin
  2. Drug

    Sulfacetamide

    go.drugbank.com/drugs/DB00634
    Approved

    An anti-infective agent that is used topically to treat skin infections and orally for urinary tract infections.

    Mixtures: Prascion RA, Prascion RA Cream with Sunscreens
  3. Drug

    Allogeneic processed thymus tissue

    go.drugbank.com/drugs/DB16736
    Approved

    patients with congenital athymia: this marks the first and only FDA-approved treatment for such therapeutic indication. … [A239814] On October 8, 2021, FDA approved allogeneic processed thymus tissue-agdc, under the market name RETHYMIC, as a one-time regenerative tissue-based therapy for immune reconstitution in pediatric

  4. Drug

    Fecal microbiota

    go.drugbank.com/drugs/DB17743
    ApprovedInvestigational

    [A259172] REBYOTA, a live fecal microbiota suspension for rectal use, was approved by the FDA in November 2022. … Fecal microbiota, given either as a rectal transplant or in an oral formulation of live spores, is an FDA-approved option to prevent the recurrence of _Clostridioides difficile_ infection (CDI) in patients

  5. Drug

    Exagamglogene autotemcel

    go.drugbank.com/drugs/DB15572
    ApprovedInvestigational

    It was approved by the FDA in December 2023 for the treatment of patients with SCD with recurrent vaso-occlusive crises. … [L49246] In January 2024, exagamglogene autotemcel received an additional FDA approval for the treatment of transfusion-dependent β-thalassemia.

  6. Drug

    Asparaginase Erwinia chrysanthemi

    go.drugbank.com/drugs/DB08886
    ApprovedInvestigational

    [L149] In June 2021, the recombinant form of asparaginase _Erwinia chrysanthemi_ was approved by the FDA as a component of a chemotherapy regimen to treat acute lymphoblastic leukemia and lymphoblastic … [A236359] Asparaginase _Erwinia chrysanthemi_ was first approved by the FDA in November 2011 to treat patients with acute lymphoblastic leukemia (ALL) who are allergic to _E. coli_-derived asparaginase

  7. Drug

    Acemetacin

    go.drugbank.com/drugs/DB13783
    ApprovedInvestigational

    Acemetacin is a carboxymethyl ester of indometacin. It is a potent non-steroidal anti-inflammatory drug, derived from the indol-3-acetic acid, whose activity is thought to be mainly through its active metabolite indomethacin. In clinical...

  8. Drug

    Velpatasvir

    go.drugbank.com/drugs/DB11613
    ApprovedInvestigational

    Velpatasvir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus ...

  9. Drug

    Candesartan cilexetil

    go.drugbank.com/drugs/DB00796
    ApprovedInvestigational

    Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is administered orally as the prodrug, candesartan cilexetil, which is rapidly converted to its active metabolite,...

    Mixtures: Nra-candesartan Hctz, Nra-candesartan HctzProducts: Nra-candesartan
  10. Drug

    Aurothioglucose

    go.drugbank.com/drugs/DB09121
    ApprovedWithdrawn

    compounds that were indicated for rheumatoid arthritis therapy have since been replaced with the use of various current disease modifying anti-rheumatic drugs (DMARDs) like methotrexate and others, which are far